We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » Pharmaceuticals » GMPs

GMPs
GMPs RSS Feed RSS

German Regulators Cite Documentation, Data Integrity at India Simvastatin Lab

September 16, 2016
Regulators in Germany have cited a lab in India with litany of GMP violations and have recommended a prohibition of supply. Read More

Chinese Plants’ Data Management, Sanitation Problems Cited in FDA Warnings

September 10, 2016
The FDA has faulted an API maker for a host of failings at its production facility in China, including tampering with official records. Read More

German Regulators Discover 35 Issues with Lab in India

August 19, 2016
Five of the violations are listed as major deficiencies. Read More

EU Regulators Push for Suspension of Chinese API Maker’s License

August 18, 2016
Spanish regulators are recommending EU officials suspend a manufacturing certificate from a Chinese API maker over repeated issues at its plant. Read More

Chinese Drugmaker Lands Warning Letter for Data Mishandling

August 18, 2016
The FDA has faulted an API maker for a host of failings at its production facility in China, including tampering with official records. Read More

German Regulators Find 35 Issues With Lab in India

August 15, 2016
Regulators in Germany have cited a lab in India with litany of GMP violations and have recommended a prohibition of supply. Read More

NIH Permanently Stops Production at Site Scrutinized by FDA

August 11, 2016
Development site had been decommissioned due to significant GMP violations. Read More

ASP Criticized for Compounding Drugs Without Approval

August 8, 2016
Company cited for producing misbranded and adulterated drugs at facility. Read More

Warning Letter Faults Chinese Firm for Data Mishandling

August 8, 2016
FDA cited Xiamen Origin for three primary deficiencies found at Fujian facility. Read More

EU Urged to Suspend License of Chinese API Maker

August 5, 2016
Company has been in violation of GMP standards since June 2015. Read More

FDA Warns Compounder Over Lack of Prescriptions, Adulterated Products

August 2, 2016
A compounding operation in Texas has landed an FDA warning letter for compounding drugs without prescriptions and for sterility concerns. Read More

FDA Parcels Out Warning Letter for Data Mishandling

August 2, 2016
The FDA has faulted an API maker for a host of failings at its production facility in China, including tampering with official records. Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 59 60 Next

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 27Jul

    Applying the Lessons of the Pandemic to Your Upcoming Trial

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FX Receives FDA Clearance for Its FX V135 Shoulder Arthroplasty Platform

  • FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants

  • FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek

  • Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing